Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.
Marco FilettiPasquale LombardiRosa FalconeRaffaele GiustiDiana GiannarelliAntonella CarcagnìValeria AltamuraGiovanni ScambiaGennaro DanielePublished in: Exploration of targeted anti-tumor therapy (2023)
Based on the network meta-analysis, alectinib and lorlatinib emerged as the most promising upfront treatment options. These treatments provide prolonged disease control while maintaining an acceptable safety profile.